137 related articles for article (PubMed ID: 30677105)
21. Concentrated insulins in current clinical practice.
Schloot NC; Hood RC; Corrigan SM; Panek RL; Heise T
Diabetes Res Clin Pract; 2019 Feb; 148():93-101. PubMed ID: 30583034
[TBL] [Abstract][Full Text] [Related]
22. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.
Morrow L; Hompesch M; Guthrie H; Chang D; Chatterjee DJ
Diabetes Obes Metab; 2011 Jan; 13(1):75-80. PubMed ID: 21114606
[TBL] [Abstract][Full Text] [Related]
23. Insulin analogs: Glimpse on contemporary facts and future prospective.
Sharma AK; Taneja G; Kumar A; Sahu M; Sharma G; Kumar A; Sardana S; Deep A
Life Sci; 2019 Feb; 219():90-99. PubMed ID: 30639280
[TBL] [Abstract][Full Text] [Related]
24. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
25. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
Owens DR; Bolli GB
Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
[TBL] [Abstract][Full Text] [Related]
26. Clinical use of the co-formulation of insulin degludec and insulin aspart.
Kumar A; Awata T; Bain SC; Ceriello A; Fulcher GR; Unnikrishnan AG; Arechavaleta R; Gonzalez-Gálvez G; Hirose T; Home PD; Kaku K; Litwak L; Madsbad S; Pinget M; Mehta R; Mithal A; Tambascia M; Tibaldi J; Christiansen JS
Int J Clin Pract; 2016 Aug; 70(8):657-67. PubMed ID: 27384031
[TBL] [Abstract][Full Text] [Related]
27. Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes.
Chatterjee S; Khunti K; Davies MJ
Drugs; 2019 Feb; 79(2):173-186. PubMed ID: 30623349
[TBL] [Abstract][Full Text] [Related]
28. Integrating advances in insulin into clinical practice: Overview of current insulin formulations.
Rhinehart AS
J Fam Pract; 2013 Sep; 62(9 Suppl Insulin):S4-8. PubMed ID: 24080572
[TBL] [Abstract][Full Text] [Related]
29. New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.
Becker RH; Dahmen R; Bergmann K; Lehmann A; Jax T; Heise T
Diabetes Care; 2015 Apr; 38(4):637-43. PubMed ID: 25150159
[TBL] [Abstract][Full Text] [Related]
30. LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.
Zhang X; Lam ECQ; Seger ME; Coutant D; Chua L; Tan LH; Soon D; Linnebjerg H
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):556-563. PubMed ID: 28940840
[TBL] [Abstract][Full Text] [Related]
31. [New insulin types in type 1 diabetes mellitus].
Mesa J
Med Clin (Barc); 2015 Jul; 145(2):70-5. PubMed ID: 25200067
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
Ericsson Å; Pollock RF; Hunt B; Valentine WJ
J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
[TBL] [Abstract][Full Text] [Related]
33. A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus.
Woo VC
Clin Ther; 2017 Aug; 39(8S2):S12-S33. PubMed ID: 28187863
[TBL] [Abstract][Full Text] [Related]
34. A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.
Haahr H; Fita EG; Heise T
Clin Pharmacokinet; 2017 Apr; 56(4):339-354. PubMed ID: 27696221
[TBL] [Abstract][Full Text] [Related]
35. Basal insulins: Pharmacological properties and patient perspectives.
Abrahamson MJ
Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887
[TBL] [Abstract][Full Text] [Related]
36. Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
Bailey TS; Pettus J; Roussel R; Schmider W; Maroccia M; Nassr N; Klein O; Bolli GB; Dahmen R
Diabetes Metab; 2018 Feb; 44(1):15-21. PubMed ID: 29153485
[TBL] [Abstract][Full Text] [Related]
37. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.
Hartmann T; Overhagen S; Ouwens DM; Raschke S; Wohlfart P; Tennagels N; Wronkowitz N; Eckel J
Cardiovasc Diabetol; 2016 Jul; 15():96. PubMed ID: 27422524
[TBL] [Abstract][Full Text] [Related]
38. The past, present, and future of basal insulins.
Pettus J; Santos Cavaiola T; Tamborlane WV; Edelman S
Diabetes Metab Res Rev; 2016 Sep; 32(6):478-96. PubMed ID: 26509843
[TBL] [Abstract][Full Text] [Related]
39. Current Status of Weekly Insulin Analogs and Their Pharmacokinetic/Pharmacodynamic Evaluation by the Euglycemic Clamp Technique.
An N; Wang X; He A; Chen W
Clin Pharmacol Drug Dev; 2023 Sep; 12(9):849-855. PubMed ID: 37439495
[TBL] [Abstract][Full Text] [Related]
40. Insulin degludec. Uncertainty over cardiovascular harms.
Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
